Stocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, ...
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...
After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, ...
Novavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback